Vericel (VCEL) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Vericel Reports Second Quarter 2022 Financial Results
August 3, 2022 7:55 AM EDTSecond Quarter Total Net Revenue of $37.0 Million
MACI Net Revenue of $28.6 Million
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights
Total net revenue of $37.0 millionMACI® net revenue of $28.6 million,... More